Last update at 2025-01-21T14:52:00Z
Is Summit Therapeutics (SMMT) the Best Russell 2000 Stock to Invest in According to Analysts?
Sat 18 Jan 25, 10:52 PMBioNTech Positioned For Solid Growth Amid Oncology Transition: Analyst
Fri 10 Jan 25, 07:54 PMSummit Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Tue 07 Jan 25, 12:00 PMWhy Is Summit Therapeutics Inc. (SMMT) Among the Best Multibagger Stocks to Buy Right Now?
Wed 01 Jan 25, 05:45 PMIs Summit Therapeutics Inc. (SMMT) the Best Performing Biotech Stock in 2024?
Mon 23 Dec 24, 03:36 PMWhy Did Summit Therapeutics Inc. (SMMT) Jump Yesterday?
Fri 20 Dec 24, 03:21 PMHere's Why Summit Therapeutics Stock Price Rose 6% on Friday
Mon 09 Dec 24, 01:13 PM2 Hot Biopharma Stocks to Buy and Hold for 5 Years
Fri 08 Nov 24, 12:00 AMUp Over 600% in 2024, Can Summit Therapeutics Stock Keep Rising?
Thu 24 Oct 24, 12:00 AMBreakdown | 2023-01-31 | 2022-01-31 | 2021-01-31 | 2020-01-31 | 2019-01-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2023-01-31 | 2022-01-31 | 2021-01-31 | 2020-01-31 | 2019-01-31 |
Income before tax | -78.78200M | -88.60200M | -52.91000M | 4.99M | 6.60M |
Minority interest | - | - | - | - | 0.00000M |
Net income | -74.38100M | -86.14700M | -52.69700M | 4.99M | 9.87M |
Selling general administrative | 26.70M | 23.61M | 19.23M | - | 16.19M |
Selling and marketing expenses | - | - | - | - | - |
Gross profit | 0.70M | 1.81M | 0.86M | 43.01M | 56.39M |
Reconciled depreciation | 2.51M | 2.46M | 2.00M | - | 1.49M |
Ebit | -72.08900M | -88.64100M | -53.19300M | -25.55600M | 12.38M |
Ebitda | -60.80300M | -86.18600M | -51.47500M | 15.16M | 13.87M |
Depreciation and amortization | 11.29M | 2.46M | 1.72M | 0.52M | 1.49M |
Non operating income net other | - | - | - | - | 0.00000M |
Operating income | -72.08900M | -86.18600M | -53.19300M | 15.16M | 12.38M |
Other operating expenses | 64.28M | 88.00M | 53.19M | -39.18200M | 47.69M |
Interest expense | 4.40M | 0.28M | 0.26M | 0.00000M | 0.56M |
Tax provision | - | 0.00000M | -0.21300M | - | -3.27366M |
Interest income | - | 0.00000M | 0.00400M | - | 0.00525M |
Net interest income | -4.40100M | -0.28100M | -0.25100M | - | 3.10M |
Extraordinary items | - | - | - | - | 0.00000M |
Non recurring | - | - | - | - | 0.00000M |
Other items | - | - | - | - | 0.00000M |
Income tax expense | -4.40100M | -2.45500M | -0.21300M | -3.84436M | -3.27366M |
Total revenue | 0.70M | 1.81M | 0.86M | 43.01M | 56.41M |
Total operating expenses | 64.28M | 88.00M | 53.19M | -39.18200M | 47.69M |
Cost of revenue | - | - | - | - | 0.02M |
Total other income expense net | -6.69300M | -2.41600M | 0.28M | -10.16200M | -5.78267M |
Discontinued operations | - | - | - | - | 0.00000M |
Net income from continuing ops | -78.78200M | -88.60200M | -52.69700M | - | 9.87M |
Net income applicable to common shares | -78.78200M | -88.60200M | -52.69700M | -24.03491M | 7.53M |
Preferred stock and other adjustments | - | - | - | - | 0.00000M |
Breakdown | 2024-01-31 | 2023-01-31 | 2022-01-31 | 2021-01-31 | 2020-01-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2024-01-31 | 2023-01-31 | 2022-01-31 | 2021-01-31 | 2020-01-31 |
Total assets | 202.95M | 664.17M | 113.37M | 102.50M | 24.44M |
Intangible assets | - | - | 10.40M | 11.52M | 10.60M |
Earning assets | - | - | - | - | - |
Other current assets | 0.18M | 0.49M | 1.20M | 1.52M | 5.80M |
Total liab | 125.26M | 537.51M | 30.09M | 23.05M | -18.09800M |
Total stockholder equity | 77.69M | 126.65M | 83.28M | 79.45M | 42.54M |
Deferred long term liab | - | - | - | - | - |
Other current liab | 0.72M | 16.97M | 12.22M | 4.99M | 1.49M |
Common stock | 7.02M | 2.11M | 0.98M | 0.83M | 3.36M |
Capital stock | 7.02M | 2.11M | 0.98M | 0.83M | - |
Retained earnings | -993.25800M | -378.33000M | -299.54800M | -214.74000M | -97.61900M |
Other liab | - | 1.43M | 2.78M | 3.08M | 3.98M |
Good will | 1.89M | 1.80M | 2.01M | 2.03M | 1.81M |
Other assets | - | 0.58M | 25.52M | - | -16.37700M |
Cash | 71.42M | 348.61M | 71.79M | 66.42M | 26.86M |
Cash and equivalents | - | - | - | - | - |
Total current liabilities | 20.41M | 38.78M | 25.62M | 19.89M | -1.83600M |
Current deferred revenue | 14.21M | - | 7.94M | 8.37M | -0.83100M |
Net debt | 34.67M | 170.16M | -69.00900M | -65.95200M | -27.86300M |
Short term debt | 2.81M | 21.46M | 1.09M | 0.39M | -1.00500M |
Short long term debt | - | 19.77M | - | - | - |
Short long term debt total | 106.10M | 518.76M | 2.78M | 0.47M | -1.00500M |
Other stockholder equity | 1066.38M | 504.77M | 384.05M | 293.37M | 42.54M |
Property plant equipment | - | 5.08M | 3.48M | 1.28M | 1.17M |
Total current assets | 189.71M | 656.71M | 97.31M | 66.42M | 26.86M |
Long term investments | - | - | - | - | - |
Net tangible assets | - | 124.86M | 70.88M | 23.43M | 47.46M |
Short term investments | 114.82M | - | - | - | - |
Net receivables | 0.85M | 6.12M | 17.16M | 10.19M | 5.13M |
Long term debt | 100.00M | 494.54M | - | - | - |
Inventory | 2.44M | 301.50M | 7.16M | -11.71000M | - |
Accounts payable | 2.67M | 0.35M | 4.37M | 6.14M | 3.39M |
Total permanent equity | - | - | - | - | - |
Noncontrolling interest in consolidated entity | - | - | - | - | - |
Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
Accumulated other comprehensive income | -2.44800M | -1.89300M | -2.19700M | -3.79400M | - |
Additional paid in capital | - | - | - | - | - |
Common stock total equity | - | - | - | 0.83M | - |
Preferred stock total equity | - | - | - | - | - |
Retained earnings total equity | - | - | - | - | - |
Treasury stock | - | - | - | - | - |
Accumulated amortization | - | - | - | - | - |
Non currrent assets other | 5.28M | 0.58M | 0.17M | 21.26M | - |
Deferred long term asset charges | - | - | - | - | - |
Non current assets total | 13.24M | 7.46M | 16.06M | 36.08M | 13.96M |
Capital lease obligations | 6.10M | 4.45M | 2.78M | 0.47M | - |
Long term debt total | - | - | - | - | - |
Breakdown | 2023-01-31 | 2022-01-31 | 2021-01-31 | 2020-01-31 | 2019-01-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2023-01-31 | 2022-01-31 | 2021-01-31 | 2020-01-31 | 2019-01-31 |
Investments | -0.62400M | -0.30600M | -0.42100M | - | -0.41052M |
Change to liabilities | -11.41000M | -2.52400M | 7.01M | -4.03636M | -36.80500M |
Total cashflows from investing activities | -0.62400M | -0.30600M | -0.42100M | -0.28691M | -0.31300M |
Net borrowings | 520.00M | 520.00M | 520.00M | -0.35782M | -0.28100M |
Total cash from financing activities | 620.24M | 77.92M | 50.55M | 33.11M | 43.85M |
Change to operating activities | 19.05M | 3.60M | -6.60700M | 3.70M | -3.41700M |
Net income | -78.78200M | -88.60200M | -52.69700M | -25.55600M | 6.60M |
Change in cash | 576.82M | 5.37M | 2.58M | 6.76M | 8.86M |
Begin period cash flow | 71.79M | 66.42M | 63.84M | 20.10M | 26.37M |
End period cash flow | 648.61M | 71.79M | 66.42M | 26.86M | 35.23M |
Total cash from operating activities | -41.58200M | -72.58700M | -48.11100M | -26.66300M | -35.14329M |
Issuance of capital stock | 100.00M | 75.00M | 50.00M | - | 45.44M |
Depreciation | 2.51M | 2.46M | 2.00M | 1.47M | 1.49M |
Other cashflows from investing activities | - | - | -0.42100M | 0.00436M | 0.00400M |
Dividends paid | - | - | - | - | 0.00000M |
Change to inventory | - | 3.60M | -6.60700M | - | 0.00000M |
Change to account receivables | 0.97M | -1.13800M | 0.21M | 4.66M | -25.33687M |
Sale purchase of stock | - | - | - | - | 0.00000M |
Other cashflows from financing activities | 545.24M | 112.92M | 0.55M | 33.11M | -1.58830M |
Change to netincome | 26.07M | 13.63M | 4.59M | 4.49M | 3.56M |
Capital expenditures | 0.62M | 0.31M | 0.42M | 0.12M | 0.16M |
Change receivables | - | - | - | - | 0.00000M |
Cash flows other operating | - | - | - | - | 0.00000M |
Exchange rate changes | - | - | - | - | 0.00000M |
Cash and cash equivalents changes | - | - | - | - | 0.00000M |
Change in working capital | 8.62M | -0.06700M | 0.62M | 4.37M | -51.18106M |
Stock based compensation | 11.95M | 12.80M | 1.77M | - | 6.22M |
Other non cash items | 14.12M | 0.50M | -0.38500M | -28.13600M | 1.73M |
Free cash flow | -42.20600M | -72.89300M | -48.53200M | -26.78200M | -35.30723M |
Sector: Healthcare Industry: Biotechnology
Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
---|---|---|---|---|---|---|---|---|
SMMT Summit Therapeutics PLC |
1.74 9.14% | 20.77 | 6.87 | - | 753.90 | 33.10 | 6425.28 | -4.1776 |
NVO Novo Nordisk A/S |
1.59 2.02% | 80.28 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
NONOF Novo Nordisk A/S |
- -% | 78.60 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
VRTX Vertex Pharmaceuticals Inc |
3.93 0.93% | 425.93 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
REGN Regeneron Pharmaceuticals Inc |
3.68 0.54% | 685.26 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.
601 Brickell Key Drive, Miami, FL, United States, 33131
Name | Title | Year Born |
---|---|---|
Mr. Robert W. Duggan | CEO & Exec. Chairman | 1944 |
Dr. Mahkam Zanganeh D.D.S., M.B.A., MBA | Co-CEO, Pres & Director | 1970 |
Dr. Urte Gayko Ph.D. | Head of Regulatory Affairs, Quality Assurance & Safety and Director | 1971 |
Prof. Dame Kay Davies DBE, FRS CBE | Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor | 1951 |
Mr. Ankur Dhingra | Chief Financial Officer | 1976 |
Ms. Michelle Avery | Director of Investor Relations | NA |
Dr. Elaine Carla Stracker J.D., Ph.D. | Head of Compliance? & Gen. Counsel | 1961 |
Mr. Campbell Hair | Head of HR? | NA |
Dr. Anne Heatherington | Head of Clinical Devel. and Quantitative Sciences | NA |
Ms. Divya Chari | Head of Global Clinical Operations | 1968 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.